The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 07, 2017
Filed:
Jul. 22, 2015
Applicant:
The Regents of the University of California, Oakland, CA (US);
Inventors:
Kit S. Lam, Oakland, CA (US);
Ruiwu Liu, Sacramento, CA (US);
Wei Yao, El Dorado Hills, CA (US);
Nancy Lane, Hillsborough, CA (US);
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61P 19/08 (2006.01); A61P 19/02 (2006.01); A61P 19/10 (2006.01); A61K 38/10 (2006.01); A61K 38/16 (2006.01); A61K 38/08 (2006.01); A61K 38/06 (2006.01); A61K 38/07 (2006.01); A61K 38/04 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); A61K 31/663 (2006.01); C07K 7/06 (2006.01); A61K 31/66 (2006.01); C07F 9/02 (2006.01); A61K 31/00 (2006.01); A61K 31/661 (2006.01); A61K 47/48 (2006.01); C07K 5/09 (2006.01); C07K 5/103 (2006.01); C07K 5/107 (2006.01); C07K 5/11 (2006.01); A61K 35/28 (2015.01);
U.S. Cl.
CPC ...
A61K 38/06 (2013.01); A61K 31/00 (2013.01); A61K 31/66 (2013.01); A61K 31/661 (2013.01); A61K 31/663 (2013.01); A61K 35/28 (2013.01); A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 47/48084 (2013.01); A61K 47/48246 (2013.01); C07F 9/02 (2013.01); C07K 5/0817 (2013.01); C07K 5/101 (2013.01); C07K 5/1016 (2013.01); C07K 5/1019 (2013.01); C07K 7/06 (2013.01); A61K 38/00 (2013.01);
Abstract
The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the αβintegrin on mesenchymal stem cells and for the surface of bone.